Boston Scientific Corporation has taken a significant step in its financial strategy by entering into underwriting agreements for a total of $3 billion in senior notes. This move, announced on November 19, 2026, is intended to bolster the company's financial resources as it prepares to acquire Penumbra, Inc., a deal that has been in the works since January 2026.
The offering includes a variety of notes, with $1 billion in 5.375% Senior Notes due 2029, $750 million in 5.500% Senior Notes due 2031, and additional amounts due in 2033 and 2036. Additionally, the company has arranged for €4.25 billion in euro-denominated senior notes, further diversifying its financing options.
This financial maneuver is crucial as Boston Scientific aims to strengthen its position in the surgical and medical instruments industry, specifically targeting innovations and advancements that come with the acquisition of Penumbra. The expected closing date for these offerings is December 1, 2026.
Background
Boston Scientific Corporation, incorporated in Delaware, operates primarily in the surgical and medical instruments and apparatus sector, classified under SIC 3841. The company trades on the New York Stock Exchange under the ticker symbol BSX. With a focus on developing medical solutions, Boston Scientific has been a key player in the healthcare industry, consistently evolving through strategic acquisitions and partnerships.
What the Filing Says
The SEC filing indicates that on November 19, 2026, Boston Scientific entered into an Underwriting Agreement for the pricing of $3 billion in senior notes. The filing specifies, "The Offerings are expected to close on December 1, 2026," highlighting the urgency and importance of this financing strategy.
Impact
This financing initiative is expected to have significant implications for Boston Scientific and its stakeholders. The funds raised will not only support the acquisition of Penumbra but also allow for general corporate purposes, which may include reducing short-term debt and funding working capital. As competitors in the surgical and medical instruments industry observe these developments, they may need to adapt their strategies to maintain their market positions.
What's Next
The next steps for Boston Scientific involve the closing of the offerings on December 1, 2026, and the subsequent integration of Penumbra into its operations, should the acquisition proceed as planned. The filing does not specify any further actions beyond this.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




